Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Xencor, Inc.
Kaiser Permanente
Duke University
University of Colorado, Denver
Roswell Park Cancer Institute
Unity Health Toronto
City of Hope Medical Center
Novartis
National Institutes of Health Clinical Center (CC)
Var2 Pharmaceuticals
NantCell, Inc.
AstraZeneca
University of Pittsburgh
Tempus AI
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
University of Calgary
A2 Biotherapeutics Inc.
Sahlgrenska University Hospital
Centre Hospitalier de Valence
Palleon Pharmaceuticals, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
Apollomics Inc.
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
Columbia University
Memorial Sloan Kettering Cancer Center
Stanford University
PureTech
Rutgers, The State University of New Jersey
Stanford University
Universidade Federal de Pernambuco
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
European Organisation for Research and Treatment of Cancer - EORTC
VA Office of Research and Development
ADC Therapeutics S.A.
Washington University School of Medicine
University of Southern California
HiberCell, Inc.
Aurigene Discovery Technologies Limited
Lebanese University
pharmaand GmbH
Klus Pharma Inc.
Kineta Inc.
Eastern Cooperative Oncology Group
University of Michigan Rogel Cancer Center
Blue Note Therapeutics
Roswell Park Cancer Institute